CollPlant Secures European Patent for Collagen-Based Formulations

The latest update is out from Collplant Holdings ( (CLGN) ).

On June 4, 2025, CollPlant Biotechnologies announced that it secured a European patent allowance for its collagen-based formulations used in soft tissue fillers and implants. This patent, effective until 2041, is a strategic move to strengthen CollPlant’s position in the growing markets for aesthetic and reconstructive procedures, with the injectable soft-tissue fillers market estimated at over $6 billion and the breast implants market at over $3 billion. The patent enhances CollPlant’s competitive edge by protecting its proprietary technology, particularly in Europe, a key target market.

The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

The overall score of 48 reflects significant financial challenges, marked by drastic revenue and cash flow declines. While technical analysis provides some positive signals, the valuation remains poor due to negative earnings. Despite promising advancements in preclinical programs and a stable cash runway, the financial outlook remains concerning.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen). The company operates in the fields of tissue repair, aesthetics, and organ manufacturing, with a strong emphasis on 3D bioprinting of tissues and organs.

Average Trading Volume: 66,626

Technical Sentiment Signal: Sell

Current Market Cap: $26.12M

For an in-depth examination of CLGN stock, go to TipRanks’ Stock Analysis page.